Observational Study With Mixtard® 30 NovoLet® to Assess Patient Satisfaction

Novo Nordisk A/S1,330 enrolled

Overview

This study is conducted in Asia. The aim of this study is to assess patient satisfaction after switching to biphasic human insulin 30 treatment using the NovoLet® insulin device as treatment for diabetes mellitus under normal clinical practice setting.

Study Type

OBSERVATIONAL

Enrollment

1,330

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

biphasic human insulin 30DRUG

Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Diabetes mellitus (type 1 or type 2) * Patient not presently using Mixtard® 30 NovoLet®

Locations (1)

Novo Nordisk Investigational Site

Manila, Philippines

Outcomes

Primary Outcomes

Change in Diabetes Treatment Satisfaction Questionnaire (DTSQ) score

Secondary Outcomes

Adverse events

Technical complaints of NovoLet® device

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.